» Articles » PMID: 37752217

Lung Microbiome As a Treatable Trait in Chronic Respiratory Disorders

Overview
Journal Lung
Specialty Pulmonary Medicine
Date 2023 Sep 26
PMID 37752217
Authors
Affiliations
Soon will be listed here.
Abstract

Once thought to be a sterile environment, it is now established that lungs are populated by various microorganisms that participate in maintaining lung function and play an important role in shaping lung immune surveillance. Although our comprehension of the molecular and metabolic interactions between microbes and lung cells is still in its infancy, any event causing a persistent qualitative or quantitative variation in the composition of lung microbiome, termed "dysbiosis", has been virtually associated with many respiratory diseases. A deep understanding of the composition and function of the "healthy" lung microbiota and how dysbiosis can cause or participate in disease progression will be pivotal in finding specific therapies aimed at preventing diseases and restoring lung function. Here, we review lung microbiome dysbiosis in different lung pathologies and the mechanisms by which these bacteria can cause or contribute to the severity of the disease. Furthermore, we describe how different respiratory disorders can be caused by the same pathogen, and that the real pathogenetic mechanism is not only dependent by the presence and amount of the main pathogen but can be shaped by the interaction it can build with other bacteria, fungi, and viruses present in the lung. Understanding the nature of this bacteria crosstalk could further our understanding of each respiratory disease leading to the development of new therapeutic strategies.

Citing Articles

A mass spectrometry-based strategy for investigating volatile molecular interactions in microbial consortia: unveiling a -specific induction of an antifungal compound.

Azzollini A, Sgorbini B, Lecoultre N, Bicchi C, Wolfender J, Rubiolo P Front Microbiol. 2025; 15:1417919.

PMID: 40070966 PMC: 11895703. DOI: 10.3389/fmicb.2024.1417919.


Tyndallized bacteria prime bronchial epithelial cells to mount an effective innate immune response against infections.

Di Vincenzo S, Di Sano C, DAnna C, Ferraro M, Malizia V, Bruno A Hum Cell. 2024; 37(4):1080-1090.

PMID: 38814518 PMC: 11194193. DOI: 10.1007/s13577-024-01080-z.


LUNG Year in Review: 2023.

Dicpinigaitis P Lung. 2024; 202(1):1-4.

PMID: 38305892 DOI: 10.1007/s00408-024-00671-9.

References
1.
Zitvogel L, Daillere R, Roberti M, Routy B, Kroemer G . Anticancer effects of the microbiome and its products. Nat Rev Microbiol. 2017; 15(8):465-478. DOI: 10.1038/nrmicro.2017.44. View

2.
Huffnagle G, Dickson R, Lukacs N . The respiratory tract microbiome and lung inflammation: a two-way street. Mucosal Immunol. 2016; 10(2):299-306. PMC: 5765541. DOI: 10.1038/mi.2016.108. View

3.
Chotirmall S, Gellatly S, Budden K, Mac Aogain M, Shukla S, Wood D . Microbiomes in respiratory health and disease: An Asia-Pacific perspective. Respirology. 2017; 22(2):240-250. DOI: 10.1111/resp.12971. View

4.
Budden K, Shukla S, Rehman S, Bowerman K, Keely S, Hugenholtz P . Functional effects of the microbiota in chronic respiratory disease. Lancet Respir Med. 2019; 7(10):907-920. DOI: 10.1016/S2213-2600(18)30510-1. View

5.
Erb-Downward J, Thompson D, Han M, Freeman C, McCloskey L, Schmidt L . Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS One. 2011; 6(2):e16384. PMC: 3043049. DOI: 10.1371/journal.pone.0016384. View